Oct. 22 at 11:29 PM
$SPRO GSK already holds a license agreement with
$SPRO, they can benefit from product sales simply by paying the agreed royalties, without the need to purchase the entire company. A buyout would only make strategic sense if GSK sought full control, higher profit margins, or other long term advantages that the current license arrangement does not provide. So if you are a long term investor, you will profit on both scenarios.
